Levonadifloxacin (WCK 771) is a novel broad-spectrum anti-methicillin-resistant (MRSA) agent recently launched in India. Five process impurities and one degradation impurity were synthesized as reference standards for their quantification by high-performance liquid chromatography (HPLC) methodology in drug substance and drug product. These compounds are not easily commercially available. The synthesis and characterization of these impurities are discussed in detail.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582070 | PMC |
| http://dx.doi.org/10.1021/acsomega.1c04639 | DOI Listing |
Publication Analysis
Top Keywords
levonadifloxacin wck
8
wck 771
8
efficient synthesis
4
synthesis potential
4
potential impurities
4
impurities levonadifloxacin
4
771 levonadifloxacin
4
771 novel
4
novel broad-spectrum
4
broad-spectrum anti-methicillin-resistant
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!